Publications by authors named "Katie Parisio"
Background: Anti-GD2 antibodies are key components of treatment for high-risk neuroblastoma; however, they cause neuropathic pain. Yoga therapy may help reduce pain and distress associated with anti-GD2 therapy.
Procedure: Children 3 years of age or older with neuroblastoma participated in individualized yoga therapy while receiving the anti-GD2 antibody dinutuximab (DIN).
Article Synopsis
- Intervention fidelity is crucial in randomized controlled trials as it can impact the effectiveness and outcomes of the intervention being tested, especially for attention control groups where reporting has been inadequate.
- The study aims to enhance fidelity in the attention control arm of a pediatric palliative care trial that evaluates a communication intervention for parents of children with cancer, contrasting it with structured educational discussions on cancer topics.
- Researchers implemented NIH guidelines to design the attention control arm, train care team dyads, and monitor quality to ensure consistency in the conduct of both intervention groups.
In this report, we describe the case of an adolescent male with an unusual case of fusion-negative, paratesticular alveolar rhabdomyosarcoma who presented with spontaneous tumour lysis syndrome and diffuse bony metastases throughout the axial and appendicular skeleton with additional significant bone marrow involvement. Both spontaneous tumour lysis syndrome and diffuse bony metastases are extremely unusual for rhabdomyosarcoma. On the backbone of standard vincristine, dactinomycin and cyclophosphamide (VAC) chemotherapy, the only local control was orchiectomy at 15 weeks, with no radiation administered due to the initially diffuse nature of the disease and rapid response to chemotherapy.
View Article and Find Full Text PDFObjective: We sought to describe palliative care services available to children with cancer along with pediatric oncologists' current and ideal practices of palliative care involvement in children with cancer.
Design: A novel survey tool was administered via REDCap to attending pediatric oncologists in the United States. The survey remained open from June to September 2020.